Current Issues of Pharmacy and Medical Sciences

Could osteoprotegerin serve as a marker of metabolic syndrome?

Current Issues in Pharmacy and Medical Sciences Vol. 26, No. 3, Pages 309-312

ANNA MARIA DĄBROWSKA1*, JERZY S.TARACH1, BEATA WOJTYSIAK-DUMA2,
ARLETA MALECHA-JĘDRASZEK2, ANNA TORUŃ-JURKOWSKA3, JANUSZ KUDLICKI4,
HELENA DONICA2

 
1 Department of Endocrinology, Medical University, Lublin, Poland
2 Department of Biochemical Diagnostics, Chair of Laboratory Diagnostics, Medical University, Lublin, Poland
3 Department of Mathematics and Medical Biostatistics, Medical University, Lublin, Poland

4 Department of Cardiology, Medical University, Lublin, Poland


DOI: 10.12923/j.2084-980X/26.3/a.15

Abstract

There has been a dramatic increase in the worldwide prevalence of obesity, which is associated with the development of several chronic diseases such as metabolic syndrome, type 2 diabetes and cardiovascular diseases. Osteoprotegerin is a glycoprotein mainly secreted by bone but produced also by heart muscle and blood vessels. It inhibits the recruitment, proliferation, and activation of 
osteoclasts. The role of osteoprotegerin in the pathogenesis of metabolic syndrome, type 2 diabetes and cardiovascular diseases is still discussed. The study was carried out on 62 patients with metabolic syndrome aged 35-83 (34F and 28M). Type 2 diabetes was diagnosed in 76% of subjects and 62% of them suffered from coronary artery disease as a macrovascular complication. 
Determinations of biochemical parameters and anthropometric measurements were performed in the studied group. The relationships between serum osteoprotegerin concentrations and components of metabolic syndrome and total cholesterol, LDL-cholesterol, HbA1C, BMI, levels of calcium and phosphate in the blood and 24-hour urinary calcium have been analysed. Diabetics had higher osteoprotegerin concentrations than patients without diabetes (5.570 pmol/l vs 4.690 pmol/l). Osteoprotegerin levels in patients with diabetes and coronary artery disease were significantly higher (6.640pmol/l) than in those without macrovascular complications (5.295 pmol/l) (Z=1.986; p=0.047). Furthermore, the associations between osteoprotegerin and calcium and phosphate levels in the blood and 24-hour urinary calcium have been shown. A lower calcium level in the blood was negative but a lower phosphate level was positive correlated with OPG serum concentration (respectively: 6.825 pmol/l vs 5.195 pmol/l, Z=2.656, p=0.008; 4.250pmol/l vs 5.640 pmol/l, Z=2.718, p=0.007). What’s more, the inverse correlations between OPG concentrations and 24-hour urinary calcium and diastolic blood pressure have been observed. No associations between osteoprotegerin and waist circumference, BMI, cholesterol levels and HbA1C, were found. In summary, osteoprotegerin is not
a use ful marker of all components of metabolic syndrome. It is level depends on the presence of hypertension, type 2 diabetes and coronary artery disease. This glycoprotein may serve a a marker of calcium and phosphate homeostasis. We concluded that the relationship between osteoprotegerin concentrations and calcification of atherosclerotic plaques in patients with metabolic syndrome and type 2 diabetes should be analysed in further investigations. 

Files to download

Keywords

osteoprotegerin, metabolic syndrome, type 2 diabetes, calcium, phosphate, atherosclerosis

References

  1. Avignon A., Sultan A., Piot C. et al. Osteoprotegerin : a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients. Diabetes Care, 30, 2934, 2007.
  2. Avignon A., Sultan A., Piot C. et al. Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diabetes Care, 28, 2176, 2005.
  3. Burakowska-Korzon A., Burakowski S. The role of osteoprotegerin/RANKL/RANK axis in diabetes complications and coronary heart disease. Diabetol. Prakt., 5, 161, 2007.
  4. Campenhout A.V., Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis., 204, 321, 2009.
  5. Janda K., Krzanowski M., Chowaniec E. et al. Osteoprotegerin as a marker of cardiovascular pisk in peritoneal dialysis patients. Pol. Arch. Med. Wewn.,123, 149, 2013.
  6. Kiechl S., Schett G., Wenning G. et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation, 109, 2175, 2004.
  7. Kilińska L., Bogdański P., Szulińska M. et al. The significance of osteoprotegerin in cardiovascular diseases. Farm. Współ., 2, 151, 2009.
  8. Knudsen S.T., Foss C.H., Poulsen P.L. et al. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur. J. Endocrinol., 149, 39, 2003.
  9. Kozakowski J. (2011). Otyłość. In: Wielka Interna. Endokrynologia część II. Zgliczyński W. (editor). Warszawa: Medical Tribune Polska; p. 831.
  10. Nabipour I., Kalantarhormozi M., Larijani B. et al. Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal women. Metabolism., 59, 742, 2010.
  11. Park J.S., Cho M.H., Nam J.S. et al. Effect of pioglitazone on serum concentartion of osteoprotegerin in patients with type 2 diabetes mellitus. Eur. J. Endocrinol., 164, 69, 2011.
  12. Pereira G.B., Tibana R.A., Navalta J. et al. Acute effects of resistance training on cytokines and osteoprotegerin in women with metabolic syndrome. Clin. Physiol. Funct. Imaging, 33, 122, 2013.
  13. Rezg R., Barreto F.C., Barreto D.V. et al. Inhibitors of vascular calcification as potential therapeutic targets. J.Nephrol., 24, 416, 2011.
  14. Sieradzki J. (2012). Cukrzyca i zespół metaboliczny. In: Interna Szczekliwa. Podręcznik chorób wewnętrznych 2012. Gajewski P. (editor). Kraków: Medycyna Praktyczna; p. 1360.
  15. Sobańska I., Odrowąż-Sypniewska G., Kuligowska M. Wpływ płci i wieku na stężenie osteoprotegeryny we krwi. Wiad. Lek., 60, 281, 2007.
prev next

 

Calendar

April 2020

Mon Tue Wed Thu Fri Sat Sun
    01 02 03 04 05
06 07 08 09 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30